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Abstract
Introduction The glomerular filtration rate (GFR), a mea-
sure of renal function, decreases by approximately 10 mL/
min every 10 years after the age of 40 years, which could
lead to the accumulation of drugs and/or renal toxicity.
Pharmacokinetic studies of drugs excreted both renally and
non-renally are desirable in patients with impaired renal
function, defined by parameters including estimated GFR
(eGFR) and creatinine clearance (CLCR).
Objective We describe here a population pharmacokinetic
analysis of the possible effects of renal impairment on
steady-state plasma concentrations of rivastigmine and its
metabolite NAP226-90 after rivastigmine patch (5 cm2
[4.6 mg/24 h], 10 cm2 [9.5 mg/24 h], 15 cm2 [13.3 mg/
24 h], and 20 cm2 [17.4 mg/24 h]) and capsule (1.5, 3, 4.5,
and 6 mg/12 h) treatment in patients with Alzheimer’s
disease.
Methods The data used to conduct the current pharma-
cokinetic analysis were obtained from the pivotal phase III,
24-week, multicenter, randomized, double-blind, placebo-
and active-controlled, parallel-group study (IDEAL). One
blood sample was collected from each patient at steady-
state to measure plasma concentrations of rivastigmine and
NAP226-90 using a liquid chromatography–tandem mass
spectrometry (LC–MS/MS) method. The steady-state
plasma concentrations of rivastigmine and NAP226-90
were plotted against CLCR and eGFR data, and boxplots
were constructed after stratification by renal function.
Results The two groups (mild/no renal impairment vs.
moderate/severe/end-stage renal impairment) showed
comparable demographic covariates for all patch sizes and
capsule doses. No correlation was observed between CLCR
or eGFR and plasma concentrations of rivastigmine or
NAP226-90. Boxplots of concentrations of rivastigmine or
NAP226-90 for each dose largely overlapped for patch and
capsule. Additionally, model-based estimates of plasma
concentrations adjusted for body weight yielded similar
results.
Conclusion The results of this study show that renal
function does not affect rivastigmine or NAP226-90
steady-state plasma concentrations, and no dose adjustment
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Key Points
We performed a large population pharmacokinetic
modeling analysis of the possible effects of renal
impairment on steady-state plasma concentrations of
rivastigmine and its metabolite, after rivastigmine
patch and capsule treatment in patients with
Alzheimer’s disease.
No correlation was observed between creatinine
clearance or estimated glomerular filtration rate and
plasma concentrations of rivastigmine or its
metabolite, indicating that renal function did not
impact steady-state plasma concentrations of
rivastigmine or its metabolite.
Consequently, no dose adjustment in patients with
renal impairment is required. This is a key finding
allowing all Alzheimer’s disease and Parkinson’s
disease dementia patients to benefit from most
optimal therapeutic doses of rivastigmine,
irrespective of their renal function status.
1 Introduction
Alzheimer’s disease (AD) and Parkinson’s disease
dementia (PDD) primarily affect older individuals aged
[65 years and their prevalence increases with age [1, 2].
The risk of renal impairment is higher in elderly people, as
shown in several longitudinal and cross-sectional studies
supporting a decline in the glomerular filtration rate (GFR)
with advancing age [3–5]. Renal impairment may result in
increased plasma concentrations of drugs and their
metabolites, potentially resulting in toxicity. It is important
to assess the renal function of patients before prescribing
drugs that are excreted renally or are known to cause renal
impairment or nephrotoxicity.
Rivastigmine is a slowly reversible (pseudo-irre-
versible), centrally selective dual inhibitor of acetyl-
cholinesterase and butyrylcholinesterase, which increases
the available acetylcholine levels and improves neuro-
transmission in AD. It has established efficacy in the
symptomatic treatment of AD [6–8] and PDD [9] and has
been shown to improve activities of daily living, cognition,
behavior, and global function [7, 10–12]. Another study
reported similar benefits of rivastigmine in more advanced
stages of the disease [13]. Studies of dose–response rela-
tionships for cholinesterase inhibitors support greater
enzyme inhibition, in turn leading to higher efficacy and
long-term benefits with higher drug doses [14].
Rivastigmine has been developed for oral twice-daily
administration as a capsule (3, 6, 9, and 12 mg/day) and
solution (2 mg/mL), and for transdermal daily adminis-
tration as a patch (5 cm2 [4.6 mg/24 h], 10 cm2 [9.5 mg/
24 h], 15 cm2 [13.3 mg/24 h], and 20 cm2 [17.4 mg/24 h])
(of note, the 20 cm2 patch has not been launched into the
market to date).
Rivastigmine is rapidly and extensively metabolized by
its target esterase enzymes, acetylcholinesterase and
butyrylcholinesterase, to NAP266-90, an inactive and non-
toxic major metabolite of rivastigmine [15], which is then
excreted renally via sulfate conjugation. Although
rivastigmine is not (or in trace amounts) excreted
unchanged in urine (2–4 % of the dose) [16, 17], investi-
gating the effects of renal function on drug exposure is
critical to ensure safe administration of the effective dose
of rivastigmine in patients. Accordingly, the US Food and
Drug Administration (FDA) draft guidance (2010), Phar-
macokinetics in Patients with Impaired Renal Function—
Study Design, Data Analysis, and Impact on Dosing and
Labeling, recommends pharmacokinetic studies in patients
with impaired renal function for drugs that are excreted
both renally and non-renally, and staging of kidney func-
tion using estimated GFR (eGFR) and creatinine clearance
(CLCR) values [18]. As described in the FDA draft guid-
ance [19], a population pharmacokinetic approach in a
phase III study with rivastigmine patch and capsule in AD
patients with renal impairment was used in place of a
specific reduced pharmacokinetic study [18]. Although
NAP226-90 is inactive and non-toxic, it was also desirable
to investigate the effects of renal function on the steady-
state plasma concentrations of NAP226-90, which is an
indicator of the extent of rivastigmine metabolism [20] and
is excreted renally, amounting to approximately 20 % of
the equivalent rivastigmine dose [16].
The current pharmacokinetic analysis aimed to evaluate
the possible effects of renal function on drug exposure. The
aim of the analysis was to compare (1) the observed
rivastigmine and NAP226-90 steady-state plasma concen-
trations in patients with either mild or no renal impairment
at baseline with the corresponding concentrations in
patients with moderate or severe renal impairment or end-
stage renal disease (ESRD); and (2) the observed steady-




The data used to conduct the pharmacokinetic analysis
described in this report were obtained from the pivotal
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phase III, 24-week, multicenter, randomized, double-blind,
placebo- and active-controlled, parallel-group study
(IDEAL [Investigation of transDermal Exelon in ALzhei-
mer’s disease]; ClinicalTrials.gov identifier
NCT00099242) [21]. The study population included 1195
elderly adults with probable AD recruited at 100 different
sites in 21 countries. The protocol, informed consent form,
any amendments, and other information given to patients
and caregivers were reviewed by an Institutional Review
Board or Independent Ethics Committee for each center. A
total of 101 Independent Ethics Committees or Institutional
Review Boards across the world were responsible to
approve these documents and forms (see Winblad et al.
[21, 22] for further details). The study was conducted
according to the ethical principles of the Declaration of
Helsinki, as revised in 2000.
The efficacy, safety, tolerability, and pharmacokinetics of
rivastigmine (Exelon) once-daily patch (5, 10, 15, and
20 cm2) and twice-daily capsule (3, 6, 9, and 12 mg/day)
formulations were evaluated in patients aged between 50 and
85 years with probable AD (Mini-Mental State Examination
[MMSE] score: 10–20) from 2003 to 2006 [21, 22]. The
capsule formulation was the active control arm. This study
provided rivastigmine and NAP226-90 (metabolite) con-
centration data on the four patch sizes (5 cm2 [4.6 mg/24 h),
10 cm2 [9.5 mg/24 h], 15 cm2 [13.3 mg/24 h], and 20 cm2
[17.4 mg/24 h]), and on the four capsule doses (3, 6, 9, and
12 mg/day). One blood sample (3 mL) was collected from
each patient to measure steady-state concentrations of
rivastigmine and its metabolite NAP226-90 in plasma. All
patients were sampled towards the end of the study period
while on their maintenance dose, i.e., after 8 weeks of
treatment with the same stable daily dose, ensuring complete
steady-state conditions (reached after a few days for both
rivastigmine and NAP226-90). Only those measurements
confirmed to be obtained at steady state were included in the
pharmacokinetic evaluation.
2.2 Pharmacokinetic Analysis
Rivastigmine and its metabolite NAP226-90 were deter-
mined in plasma by using liquid/liquid extraction followed
by liquid chromatography–tandem mass spectrometry (LC–
MS/MS) with atmospheric pressure chemical ionization
mode, with a limit of quantitation (LOQ) of 0.2 ng/mL for
both compounds, using 500 lL of human plasma [23]. The
validation of the method is described elsewhere [23]. The
study between-run variability was tested using quality con-
trol samples with low (0.4 ng/mL), medium (7.5 ng/mL),
and high (25 ng/mL) concentrations, and ranged from 1.9 to
3.9 % for rivastigmine and 6.3 to 8.3 % for NAP226-90.
According to the FDA draft guidance (2010), renal
function at baseline was quantified by CLCR in addition to
eGFR [18]. CLCR and eGFR were estimated (not mea-
sured) as follows.
CLCR was estimated by the Cockcroft-Gault method
(CLCR-CG) [24]. The equation for men (Eq. 1) is as
follows:
CLCRðmL=minÞ ¼ 1:23 ð140age ½yearsÞ weightðkgÞ
Serumcreatinine ½lmol=L
ð1Þ
The CLCR equation for women (Eq. 2) is as follows:
CLCR mL=minð Þ ¼ 1:04 140age years½ ð Þ weight kgð Þ
Serumcreatinine lmol=L½ 
ð2Þ
eGFR was estimated based on the abbreviated Modification
of Diet in Renal Disease (MDRD) formula (eGFR-MDRD)
[25, 26] as follows (Eq. 3):
eGFRðmL=min=1:73m2Þ
¼ 175  ðserum creatinine mg=dL½ Þ1:154  ðage½yearsÞ0:203
 ð0:742 if femaleÞ  ð1:212 if AfricanAmericanÞ
ð3Þ
Using the estimated values for CLCR (mL/min) and eGFR
(mL/min/1.73 m2) at baseline, patients were assigned to the
following five renal impairment groups: control/normal
renal function, C90; mild renal impairment, 60 to \90;
moderate renal impairment, 30 to \60; severe renal
impairment, 15 to\30; and ESRD\15. Due to the small
proportion of patients in certain categories, the patients were
pooled into two broader groups to facilitate comparison of
drug exposure between the groups: (1) controls and mild
renal impairment; and (2) moderate and severe renal
impairment and ESRD. The group with mild or no renal
impairment served as the ‘control group’ for comparison
with the ‘renal impairment group’ comprising patients with
moderate and severe renal impairment and ESRD. From here
on, these two groups are referred to as the control group and
the renal impairment group, respectively.
Boxplots were constructed for the observed steady-state
plasma concentrations of rivastigmine and NAP226-90
stratified by baseline renal function. The observed steady-
state plasma concentrations were plotted against CLCR and
eGFR.
A covariate search on the same study data [21] to
determine the relationship of patient demographics with
steady-state plasma concentrations of rivastigmine and
NAP226-90 showed a significant relationship between drug
exposure and body weight, which was expressed by Eqs. 4
and 5. The steady-state plasma concentrations of rivastig-
mine and NAP226-90 in patients with various body
weights relative to the steady-state plasma concentrations
in a patient weighing 65 kg were estimated as follows:
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RivastigmineSS=RivastigmineSS; 65 kg
¼ ðbodyweight=65 kgÞ1:33 ð4Þ
and
NAP22690SS=NAP22690SS; 65 kg
¼ ðbodyweight=65 kgÞ0:83 ð5Þ
where SS indicates steady state.
Using this known relationship between body weight and
plasma rivastigmine or NAP226-90 concentrations, the
analyses described above were repeated with the model-
based estimates of plasma concentrations adjusted to a
body weight of 65 kg.
3 Results
When stratified by renal impairment using CLCR and eGFR,
the two treatment patient groups showed comparable values
for demographic covariates such as age, weight, and MMSE
score at baseline across all patch sizes (Table 1) and capsule
doses (Table 2). There were no ESRD patients.
The boxplots depicting the steady-state plasma con-
centrations stratified by renal impairment (CLCR or eGFR)
for both rivastigmine and NAP226-90 largely overlapped
for both patient groups within each dose level of patch
(Fig. 1) and capsule (Fig. 2) applications. The arithmetic
means with standard deviation, and the geometric means
with 95 % confidence intervals (and geometric mean
ratios) of rivastigmine and NAP226-90 concentrations for
each patient group at each dose level are shown in Table 3
(stratified by CLCR and eGFR) for rivastigmine, Table 4
(stratified by CLCR and eGFR) for NAP226-90 following
patch application, Table 5 (stratified by CLCR and eGFR)
for rivastigmine, and Table 6 (stratified by CLCR and
eGFR) for NAP226-90 following capsule administration.
Results obtained using the body weight-adjusted concen-
trations for both rivastigmine and NAP226-90 (data not
shown) were similar to those using body weight-unadjusted
concentrations.
Table 1 Patient demographic
summaries stratified by renal
impairment: patch
Patch size (cm2) Group n Sex (M/F) MMSEa Age (years) Weight (kg)
Patient demographic summaries stratified by CLCR
5 Control 9 2/7 16.9 ± 1.8 73.8 ± 1.9 65.9 ± 11.3
5 Renal impairment 10 1/9 18.3 ± 1.5 79.0 ± 5.2 59.4 ± 10.5
10 Control 101 40/61 16.8 ± 3.3b 70.0 ± 7.7 70.6 ± 11.8
10 Renal impairment 72 21/51 16.2 ± 3.1 76.7 ± 6.4 62.8 ± 11.2
15 Control 6 3/3 16.5 ± 2.4 71.5 ± 8.3 70.0 ± 13.8
15 Renal impairment 12 4/8 15.7 ± 2.9 77.8 ± 3.5 59.8 ± 11.0
20 Control 48 19/29 16.9 ± 2.9 68.7 ± 8.3 72.8 ± 12.0
20 Renal impairment 49 17/32 16.7 ± 3.0 76.9 ± 5.8 60.5 ± 9.7
Patient demographic summaries stratified by eGFR
5 Control 15 3/12 17.5 ± 1.8 75.6 ± 3.9 60.5 ± 11.4
5 Renal impairment 4 0/4 18.2 ± 1.5 80.0 ± 6.5 69.9 ± 5.5
10 Control 136 49/87 16.5 ± 3.4c 72.2 ± 8.2 66.4 ± 12.1
10 Renal impairment 38 12/26 16.7 ± 2.5 74.6 ± 6.7 70.8 ± 11.8d
15 Control 17 6/11 15.9 ± 2.8 75.3 ± 6.1 62.0 ± 11.9
15 Renal impairment 1 1/0 17.0 82.0 83.0
20 Control 75 29/46 16.7 ± 2.9 71.8 ± 8.6 65.8 ± 12.6
20 Renal impairment 22 7/15 17.2 ± 2.9 76.4 ± 5.7 69.3 ± 11.7
The control group includes patients with no renal impairment or with mild renal impairment, and the renal
impairment group includes patients with moderate or severe renal impairment (control: C90; mild: 60 to
\90; moderate: 30 to\60; severe: 15 to\30). Of the 310 patients with steady-state pharmacokinetic
information, 3 patients had missing CLCR values and 2 had missing eGFR values
CLCR creatinine clearance, eGFR estimated glomerular filtration rate, F female, M male, MMSE Mini-
Mental State Examination
a Baseline value
b n = 100
c n = 135
d n = 37
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Table 2 Patient demographic summaries stratified by renal impairment: capsule
Capsule dose (mg daily) Group n Sex (M/F) MMSEa Age (years) Weight (kg)
Patient demographic summaries stratified by CLCR
3 Control 7 1/6 16.1 ± 3.3 71.9 ± 5.5 57.1 ± 13.3
3 Renal impairment 10 2/8 17.5 ± 2.8 71.0 ± 7.3 66.6 ± 6.1
6 Control 5 2/3 18.4 ± 2.6 74.8 ± 7.0 52.5 ± 10.6
6 Renal impairment 13 6/7 16.6 ± 3.2 69.4 ± 9.7 69.7 ± 10.0
9 Control 5 2/3 17.4 ± 1.8 76.8 ± 6.6 55.7 ± 12.3
9 Renal impairment 8 4/4 14.9 ± 3.8 65.8 ± 9.0 78.9 ± 15.8
12 Control 36 14/22 15.5 ± 3.0 76.8 ± 5.1 60.3 ± 10.1
12 Renal impairment 43 22/21 17.4 ± 2.9 69.6 ± 8.4 71.5 ± 11.4
Patient demographic summaries stratified by eGFR
3 Control 3 0/3 16.3 ± 4.0 69.0 ± 5.8 63.9 ± 5.8
3 Renal impairment 14 3/11 17.1 ± 2.9 71.9 ± 6.7 62.4 ± 11.4
6 Control 1 0/1 18.0 65.0 73.0
6 Renal impairment 17 8/9 17.1 71.2 ± 9.3 64.5 ± 12.9
9 Control 3 1/2 17.7 ± 1.5 67.3 ± 1.9 76.0 ± 12.5
9 Renal impairment 10 5/5 15.3 ± 3.6 70.8 ± 9.4 68.2 ± 19.9
12 Control 15 6/9 15.4 ± 2.5 76.1 ± 6.0 68.2 ± 12.9
12 Renal impairment 64 30/34 16.8 ± 3.1 72.1 ± 8.2 66.0 ± 12.0
The control group includes patients with no renal impairment or with mild renal impairment, and the renal impairment group includes patients
with moderate or severe renal impairment (control: C90; mild: 60 to\90; moderate: 30 to\60; severe: 15 to\30). Of the 128 patients with
steady-state pharmacokinetic information, 1 patient had a missing CLCR value and 1 had a missing eGFR value
CLCR creatinine clearance, eGFR estimated glomerular filtration rate, F female, M male, MMSE Mini-Mental State Examination
a Baseline value
Fig. 1 Rivastigmine and
NAP226-90 steady-state plasma
concentrations stratified by
baseline renal impairment as
measured by creatinine
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Fig. 2 Rivastigmine and
NAP226-90 steady-state plasma
concentrations stratified by
baseline renal impairment as
measured by creatinine




Table 3 Comparison of rivastigmine steady-state plasma concentrations by patch size stratified by baseline renal impairment



















Renal impairment measured by CLCR
5 Control 9 2.2 1.4–14.0 3.9 4.0 2.9 1.8–4.7 93.8
5 Renal impairment 10 2.7 0.6–7.2 3.5 2.3 2.7 1.7–4.5
10 Control 100 5.0 0.5–26.9 6.6 5.1 5.0 4.3–5.8 122
10 Renal impairment 72 5.9 0.7–41.0 8.8 7.8 6.1 5.0–7.5
15 Control 6 8.6 1.3–21.6 10.3 7.9 7.2 3.1–16.6 121
15 Renal impairment 12 9.5 2.9–36.6 12.1 11.1 8.7 5.4–13.9
20 Control 48 14.7 2.6–84.9 20.3 17.0 15.0 12.0–18.8 108
20 Renal impairment 49 18.1 2.7–75.8 20.7 14.6 16.2 13.2–20.0
Renal impairment measured by eGFR
5 Control 15 2.6 0.6–14.0 3.7 3.4 2.8 1.9–4.1 107
5 Renal impairment 4 3.7 1.1–5.7 3.6 2.1 3.0 1.4–6.2
10 Control 136 5.2 0.5–28.8 7.1 5.9 5.3 4.6–6.0 121
10 Renal impairment 37 5.7 0.7–41.0 9.5 9.3 6.4 4.7–8.6
15 Control 17 9.1 1.3–32.2 10.0 8.0 7.5 5.0–11.0
15 Renal impairment 1 36.6 36.6 36.6
20 Control 75 18.3 2.6–84.9 22.7 16.8 17.5 14.8–20.8 60.2
20 Renal impairment 22 11.3 2.7–30.9 13.1 7.9 10.5 7.8–14.2
The control group includes patients with no renal impairment or with mild renal impairment, and the renal impairment group includes patients
with moderate or severe renal impairment
CI confidence interval, CLCR creatinine clearance, eGFR estimated glomerular filtration rate
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3.1 Patch
In this phase III study, 515 patients in the intent-to-treat
(ITT) population received rivastigmine patch treatment.
Steady-state plasma concentrations of rivastigmine and
NAP226-90 were available in 309 and 306 of these
patients, respectively, and were used in the analysis. None
of the analyzed patients had ESRD. When stratified by
CLCR, two patients treated with the 20 cm
2 (17.4 mg/24 h)
patch and one patient treated with the 10 cm2 (9.5 mg/
24 h) patch had severe renal impairment. When stratified
by eGFR, there was one patient each in the 10 cm2
(9.5 mg/24 h) and 20 cm2 (17.4 mg/24 h) patch groups
with severe renal impairment. The control group for the
various patch sizes comprised patients with no (up to
25 %) or mild renal impairment.
Overall, the plasma concentrations for rivastigmine as
well as NAP226-90 in patients with moderate to severe
renal impairment were comparable with, or only slightly
higher or lower than, those in patients with no or mild renal
impairment. The boxplots largely overlapped for the two
patients groups within each dose level.
The average changes in rivastigmine concentrations,
depicted by the ratio of geometric means between the two
patient groups when measured using CLCR, were -6, ?22,
?21, and ?8 % for patch sizes 5 cm2 (4.6 mg/24 h),
10 cm2 (9.5 mg/24 h), 15 cm2 (13.3 mg/24 h), and 20 cm2
(17.4 mg/24 h), respectively (Table 3). The corresponding
results for NAP226-90 were ?12, ?17, -23, and ?10 %,
respectively (Table 4).
When measured using eGFR, the average changes in
rivastigmine concentrations between the two patient groups
were ?7, ?21, and -40 % for patch sizes 5 cm2 (4.6 mg/
24 h), 10 cm2 (9.5 mg/24 h), and 20 cm2 (17.4 mg/24 h),
respectively (Table 3); the changes in NAP226-90 concen-
trations were ?97, ?8, and -10 %, respectively (Table 4).
The ratio could not be estimated for rivastigmine andNAP226-
90 following the 15 cm2 (13.3 mg/24 h) patch size as only one
patient (i.e., eGFR value) was available in this dose group.
No correlations were observed between rivastigmine or
NAP226-90 plasma concentrations and the baseline values
of CLCR or eGFR as shown in the scatterplots for steady-
state plasma concentrations of rivastigmine and NAP226-
90 against CLCR and eGFR in Fig. 3. The coefficients of
correlation (R2 values) calculated using linear regression to
quantify the relationship between concentrations and CLCR
or eGFR (i.e., to quantify the fraction of pharmacokinetic
variation due to CLCR or eGFR) ranged from 0.1 to 2.5 %,
Table 4 Comparison of NAP226-90 steady-state plasma concentrations by patch size stratified by baseline renal impairment



















Renal impairment measured by CLCR
5 Control 8 2.0 1.0–4.7 2.2 1.2 1.9 1.4–2.8 112
5 Renal impairment 9 2.7 0.4–11.3 3.1 3.2 2.2 1.2–4.0
10 Control 99 3.2 0.4–9.5 3.4 1.5 2.9 2.6–3.2 117
10 Renal impairment 72 3.6 0.4–14.9 4.3 3.0 3.4 2.9–4.0
15 Control 6 5.4 3.0–17.9 8.3 6.2 6.7 3.7–11.9 76.6
15 Renal impairment 12 4.9 1.3–22.3 6.6 5.8 5.1 3.3–7.8
20 Control 48 7.8 1.8–47.0 9.1 7.4 7.2 5.9–8.7 110
20 Renal impairment 49 8.1 1.9–19.5 9.0 4.3 7.9 6.8–9.2
Renal impairment measured by eGFR
5 Control 14 2.0 0.4–4.7 2.1 1.1 1.8 1.3–2.6 197
5 Renal impairment 3 2.8 1.5–11.3 5.2 5.3 3.6 1.1–11.7
10 Control 134 3.2 0.6–14.9 3.6 2.4 3.1 2.8–3.4 108
10 Renal impairment 38 3.7 0.4–14.5 4.1 2.8 3.3 2.6–4.2
15 Control 17 4.9 1.3–17.9 6.3 4.4 5.1 3.7–7.0
15 Renal impairment 1 22.3 22.3 22.3
20 Control 75 8.2 1.8–47.0 9.3 6.6 7.7 6.7–8.9 90.0
20 Renal impairment 22 6.9 2.4–19.5 7.9 4.1 7.0 5.6–8.7
The control group includes patients with no renal impairment or with mild renal impairment, and the renal impairment group includes patients
with moderate or severe renal impairment
CI confidence interval, CLCR creatinine clearance, eGFR estimated glomerular filtration rate
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confirming that neither CLCR nor eGFR have a clear effect
on the exposure to rivastigmine or NAP226-90. The plasma
concentrations of rivastigmine or NAP226-90 did not show
any consistent trend of increasing with decreasing CLCR or
eGFR values.
3.2 Capsule
Overall, 256 patients in the ITT population received the
rivastigmine capsule formulation, and 234 of these patients
completed the study. A total of 128 patients with steady-
state plasma concentration of rivastigmine and/or NAP226-
90 were included in the analysis. There were no patients
with ESRD in the study population. Two patients treated
with rivastigmine 12 mg/day had severe renal impairment
when stratified by CLCR, but none had severe renal
impairment when stratified by eGFR. The control group for
the various capsule doses consisted of patients with no (up
to 25 %) or mild renal impairment.
The plasma concentrations for both rivastigmine and
NAP226-90 in patients with renal impairment were com-
parable to, or tended to be slightly lower (though some
cases higher) than, those in the control group.
The average changes in rivastigmine concentrations,
depicted by the ratio of geometric means between the two
patient groups when measured using CLCR, were -16,
-22, ?8, and -15 % for daily doses of 3, 6, 9, and 12 mg,
respectively (Table 5). The corresponding values for
NAP226-90 were -21, -18, ?31, and -6 %, respectively
(Table 6).
When measured using eGFR, the average changes in
rivastigmine concentrations between the two patient groups
were ?42, ?20, -30, and ?12 % for capsule daily doses
3, 6, 9, and 12 mg, respectively (Table 5); the changes in
NAP226-90 concentrations were -19, ?23, -40, and
-3 %, respectively (Table 6).
No correlations were observed between plasma con-
centrations of either rivastigmine or NAP226-90 and
baseline values of CLCR or eGFR as shown in scatterplots
(Fig. 4). The coefficients of correlation (R2 values) ranged
from 0.1 to 2.4 %, confirming that neither CLCR nor eGFR
have a clear effect on the exposure to rivastigmine or
NAP226-90. The plasma concentrations of rivastigmine or
NAP226-90 following capsule administration did not show
any consistent trend of increasing with decreasing CLCR or
eGFR values.
Table 5 Comparison of rivastigmine steady-state plasma concentrations by capsule dose stratified by baseline renal impairment



















Renal impairment measured by CLCR
3 Control 6 1.4 1.1–8.6 3.2 3.1 2.2 1.1–4.5 83.5
3 Renal impairment 3 1.5 1.5–2.9 2.0 0.8 1.9 1.2–2.8
6 Control 9 5.9 1.9–11.3 6.4 3.4 5.4 3.5–8.2 78.2
6 Renal impairment 4 4.7 2.4–6.5 4.6 1.9 4.2 2.6–6.7
9 Control 6 6.6 1.6–20.9 8.2 7.1 5.8 2.7–12.5 108
9 Renal impairment 5 9.9 0.8–27.1 12.9 12.5 6.3 1.6–25.1
12 Control 40 16.0 1.7–41.5 17.8 11.9 12.9 9.6–17.1 84.8
12 Renal impairment 35 13.6 1.6–56.9 15.9 12.4 10.9 7.9–15.0
Renal impairment measured by eGFR
3 Control 8 1.5 1.1–8.6 2.8 2.7 2.0 1.2–3.4
3 Renal impairment 1 2.9 2.9 2.9
6 Control 12 5.8 1.8–11.3 5.8 3.2 4.9 3.5–7.0
6 Renal impairment 1 5.9 5.9 5.9
9 Control 9 7.5 1.6–27.1 9.8 8.9 6.4 3.3–12.6 70.2
9 Renal impairment 2 12.9 0.8–24.9 12.9 4.5 0.2–128.1
12 Control 61 14.5 1.6–41.5 16.6 11.9 11.7 9.2–14.8 112
12 Renal impairment 14 15.5 2.0–56.9 18.0 14.1 13.0 8.0–21.2
The control group includes patients with no renal impairment or with mild renal impairment, and the renal impairment group includes patients
with moderate or severe renal impairment
CI confidence interval, CLCR creatinine clearance, eGFR estimated glomerular filtration rate
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When the analysis was repeated with model-based
estimates of plasma concentrations adjusted to a body
weight of 65 kg, it yielded similar results for the body
weight-adjusted concentrations to those obtained using the
observed unadjusted concentrations (data not shown).
Overall, no consistent and relevant differences
were observed in plasma concentrations of rivastig-
mine and NAP226-90 in patients in the renal
impairment group when compared with those in the
control group.
Table 6 Comparison of NAP226-90 steady-state plasma concentrations by capsule dose stratified by baseline renal impairment



















Renal impairment measured by CLCR
3 Control 10 1.8 0.2–4.1 1.9 1.3 1.3 0.6–2.5 78.7
3 Renal impairment 7 0.6 0.3–4.1 1.6 1.6 1.0 0.5–2.2
6 Control 13 5.0 0.6–10.8 5.1 3.3 3.6 2.1–6.2 81.7
6 Renal impairment 5 3.2 1.1–6.4 3.5 2.1 3.0 1.6–5.4
9 Control 8 4.4 1.8–11.8 5.4 3.6 4.5 2.8–7.1 131
9 Renal impairment 5 6.8 2.3–12.5 6.8 3.9 5.9 3.3–10.3
12 Control 43 8.9 1.6–41.1 10.7 7.7 8.5 6.9–10.5 93.7
12 Renal impairment 36 9.7 1.5–22.6 9.7 5.5 8.0 6.4–9.9
Renal impairment measured by eGFR
3 Control 14 1.7 0.2–4.1 1.8 1.5 1.2 0.7–2.1 80.7
3 Renal impairment 3 0.5 0.4–3.7 1.6 1.9 1.0 0.3–3.6
6 Control 17 4.8 0.6–10.8 4.7 3.2 3.4 2.2–5.3
6 Renal impairment 1 4.2 4.2 4.2
9 Control 10 6.0 1.8–12.5 6.7 3.9 5.6 3.7–8.5 60
9 Renal impairment 3 3.7 2.3–4.5 3.5 1.1 3.3 2.3–4.9
12 Control 64 9.1 1.6–41.1 10.3 6.9 8.3 7.0–9.8 97.2
12 Renal impairment 15 9.7 1.5–22.6 10.1 6.3 8.1 5.6–11.7
The control group includes patients with no renal impairment or with mild renal impairment, and the renal impairment group includes patients
with moderate or severe renal impairment
CI confidence interval, CLCR creatinine clearance, eGFR estimated glomerular filtration rate
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4 Discussion
Medical co-morbidity is highest in the elderly, who con-
stitute 6.4 % of the world’s population. These patients are
on long-term multiple medication regimens for their co-
morbidities and are the highest consumers of prescription
medicines [27]. Polypharmacy increases the risk of medi-
cation-related adverse events, and advancing age is asso-
ciated with alterations in drug pharmacokinetics. Renal
impairment is more common in elderly patients, which
increases the possibility of drug interactions, drug toxicity,
and impaired drug elimination [28]. Elderly patients are
more prone to adverse effects, leading to a decreased level
of tolerance when compared with healthy individuals, and
may require dose adjustment.
As previously demonstrated in a study exploring the
ethnic differences in the pharmacokinetics and pharmaco-
dynamics of the rivastigmine patch, urinary elimination of
unchanged rivastigmine is low, amounting to a maximum
of 4 % of the administered dose of rivastigmine [16].
Excretion of NAP226-90 was, at maximum, 20 % of the
equivalent rivastigmine dose [16]. When administered via a
transdermal patch, the amount of rivastigmine released
from the device is known to increase linearly with the patch
size, and the use of larger patch sizes translates into higher
plasma exposure to rivastigmine [29]. This might have
presented a concern for patients with compromised renal
function, particularly at high doses, as the maximum con-
centration of drug in plasma (Cmax) and area under the
plasma concentration–time curve (AUC) of rivastigmine
increase more than proportionally with dose increments
[16, 29, 30]. Similarly, for the capsule, the rivastigmine
Cmax and AUC increased over-proportionally with dose
increments [31]. The fact that rivastigmine (and NAP226-
90) is poorly excreted in urine [16] means that, so far, there
has been no need to conduct a specific study [19] in
patients with renal impairment.
However, renal impairment can adversely affect some
pathways of hepatic/gut drug metabolism and has also been
associated with other changes (absorption, plasma protein
binding, transport, and tissue distribution). These changes
may be particularly prominent in patients with severely
impaired renal function and have been observed even when
the renal route is not the primary route of elimination of a
drug. Thus, for most drugs that are likely to be adminis-
tered to patients with renal impairment, including drugs
that are not primarily excreted by the kidney, it is strongly
recommended, including by the FDA [18], that the phar-
macokinetics in patients with renal impairment be inves-
tigated to provide appropriate dosing recommendations.
Even though rivastigmine and NAP226-90 are poorly
excreted in urine, the true effect of renal impairment on
pharmacokinetic is unclear and has raised the interest of
health authorities and practitioners.
The present pharmacokinetic analyses of rivastigmine
and its inactive metabolite NAP226-90 following patch and
capsule administration in AD patients showed that the
steady-state plasma concentrations of rivastigmine and
NAP226-90 were comparable between the control and renal
impairment groups. This is a reassuring finding indicating no
safety or efficacy concerns with the use of rivastigmine
patch or capsule in patients with impaired renal function.
The plasma concentrations of both rivastigmine and
NAP226-90 largely overlapped between patient groups
within each dose level of patch or capsule when renal
function was measured using either CLCR or eGFR.
Changes in rivastigmine concentrations (determined by
the ratio of geometric means) between the two groups were
small and considered to be not clinically relevant when renal
impairment was stratified by CLCR or eGFR. Moreover,
decreasing CLCR or eGFR values were not associated with a
systematic one-way change (e.g., systematic increase) in
plasma concentrations of rivastigmine or NAP226-90. The
distribution and fluctuation (increase or decrease) of the
observed steady-state plasma concentrations after adminis-
tration of rivastigmine were comparable between the renal
impairment patients and the control group for both analytes.
The same analysis when using the body weight-adjusted
concentrations of rivastigmine or NAP226-90 resulted in the
same findings and conclusions as those with the body
weight-unadjusted observations, except for effects due to the
small patient numbers in the 5 cm2 (4.6 mg/24 h) and
15 cm2 (13.3 mg/24 h) patch groups. In addition, the plasma
concentrations of rivastigmine and NAP226-90 did not show
any clear or consistent trend between the two patient groups
who were administered capsules. Therefore, no dose
adjustment for patch or capsule formulations is required in
patients with renal impairment.
Other drugs available to treat AD such as memantine,
galantamine and donepezil are excreted unchanged by the
renal route. Dose restriction is advised with memantine,
which is excreted predominantly in urine as unchanged
drug, in part via renal tubular secretion among patients
with severe renal impairment [32]. Although pharmacoki-
netic interactions between memantine and other renally
excreted drugs have not been observed [32], drugs excreted
mainly by the renal route can pose a risk from interaction
with other concomitantly administered renally excreted
drugs in a patient with a limited renal reserve. Galantamine
is excreted unchanged in urine, representing approximately
20–25 % of the administered dose. As observed with
memantine, exposures to galantamine in patients with
moderate and severe renal impairment are higher than
those observed in healthy subjects [33]. Donepezil, another
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acetylcholinesterase inhibitor, undergoes significant first-
pass metabolism and 16.9 % of the administered dose is
excreted unchanged in urine [34]. Plasma concentrations of
donepezil were found to be numerically but not signifi-
cantly higher in patients with renal impairment relative to
the healthy controls [35]. However, a relationship trend
between exposure parameters (in particular AUC) and
CLCR was observed. Another study of donepezil extended
these findings to steady-state concentrations [36]. On the
contrary, rivastigmine administered as both patch and
capsule formulations shows insignificant renal excretion
and there was no correlation between its systemic exposure
and renal function status.
The present analysis is useful in guiding the dose deci-
sions for rivastigmine in patients with compromised renal
function as it shows that patients with renal impairment can
be administered rivastigmine at dosages similar to those
administered to patients with normal renal function, and
the dosing should be guided by disease stage and patient
tolerability to ensure optimal therapeutic dosing.
5 Conclusions
Renal function, as measured by CLCR or eGFR, does not
impact the steady-state plasma concentrations of either
rivastigmine or its inactive metabolite NAP226-90. The
concentrations of both rivastigmine and NAP226-90 in
patients with AD treated with rivastigmine patch 5 cm2
(4.6 mg/24 h), 10 cm2 (9.5 mg/24 h), 15 cm2 (13.3 mg/
24 h), and 20 cm2 (17.4 mg/24 h) or capsule (3, 6, 9, and
12 mg/day) were comparable between the control and
impaired renal function groups, indicating that patients
with renal impairment can be administered rivastigmine at
dosages similar to those administered to patients with
normal renal function.
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